Altimmune Reports Phase 2 Results For Pemvidutide In Alcohol Use Disorder, Plans FDA Meeting In December Ahead Of Phase 3
Benzinga Newsdesk 57 minutes ago
BiotechGeneralNews
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolerability profile
RECLAIM and IMPACT findings presented at AASLD further support the differentiated profile of pemvidutide, with its balanced 1:1 glucagon/GLP-1 dual receptor activity
Company scheduled to hold End-of-Phase 2 meeting with FDA in December on design of the Phase 3 registrational program for AUD
MORRISTOWN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today presented key positive results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD). The presentation took place in a late-breaker session at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD) in Denver, Colorado.